Infographic
Impact of additive PICOs in a European Joint Health Technology Assessment
Poster presented at Virtual ISPOR Europe 2022 on 6-9 November 2022
Dec 19, 2022
Download
The implementation of the EU HTA Regulation (HTAR) in 2025 will create a joint clinical assessment (JCA) for new medicines, starting with oncology and ATMPs. This will require the development of an assessment scope that "shall be inclusive and reflect Member States' needs in terms of parameters and of the information, data, analysis and other evidence to be submitted by the health technology developer " [1], particularly (a) the patient population; (b) the intervention(s) (c) the comparators and; (d) the health outcomes (known as the PICO).

Related solutions

Contact Us